Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and immunogenicity of candidate tuberculosis (TB) vaccine MVA85A administered by the intramuscular route and the intradermal route: a phase I randomised active controlled trial.

Next Previous
Search
Trial Profile

Safety and immunogenicity of candidate tuberculosis (TB) vaccine MVA85A administered by the intramuscular route and the intradermal route: a phase I randomised active controlled trial.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 31 May 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MVA 85A (Primary)
  • Indications Tuberculosis
  • Focus Adverse reactions

Most Recent Events

  • 25 Mar 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
  • 11 Aug 2010 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health).
  • 28 Dec 2009 New trial record

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top